Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 2876Carcinoma, Non-Small-Cell Lung 2430Breast Neoplasms 2070Colorectal Neoplasms 1248Neoplasm Metastasis 1233Prostatic Neoplasms 1083Melanoma 973Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 851Leukemia, Myeloid, Acute 809Lung Neoplasms 759Pancreatic Neoplasms 753Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 624Carcinoma, Hepatocellular 567Carcinoma, Renal Cell 547Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 469Head and Neck Neoplasms 452Glioblastoma 436Advanced Solid Tumors 433Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 410Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

continuous erythropoietin receptor activator 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Renal Anemia × Clear all
NCT00717366 2017-09-08

Study to Determine Optimum Intravenous Starting Dose of MIRCERA for Treatment of Pediatric Participants With Anemia and Chronic Kidney Disease on Hemodialysis

Hoffmann-La Roche

Phase 2 Completed
64 enrolled 15 charts 1 FDA
Classical hematology

Renal Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡